Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

NZ sharemarket down 1.13% for the week
Markets Market close

NZ sharemarket down 1.13% for the week

The S&P/NZX 50 Index closed at 11,796.21, down 39.83 points or 0.34%.

Graham Skellern 19 Apr 2024
Bell Potter boosts Santana target price 53.5%
Primary Sector

Bell Potter boosts Santana target price 53.5%

Aussie brokers increasingly like the look of a low-cost, high yield Otago gold play.

Pattrick Smellie 19 Apr 2024
Anna Palairet appointed Fonterra's chief operating officer
Primary Sector

Anna Palairet appointed Fonterra's chief operating officer

Having acted in the role since June last year, she replaces Fraser Whineray.

Riley Kennedy 19 Apr 2024
Analysts upbeat about Tower's latest guidance
Markets

Analysts upbeat about Tower's latest guidance

The insurer's shares have gained 36% so far this year. 

Rebecca Howard 19 Apr 2024